BLAUVELT, A. .; RICH, P.; SOFEN, H.; LAMBERT, J.; MEROLA, J.; LEBWOHL, M.; HIPPELI, L.; KISA, R.; BANERJEE, S.; KIMBALL, A. Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 4, p. s41, 2022. DOI: 10.25251/skin.6.supp.41. Disponível em: Acesso em: 10 aug. 2022.